Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Bluebird Ventures

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 11
Average round size
info
The average size of a deal this fund participated in
$88M
Portfolio companies 7
Rounds per year 2.20
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.36
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Life Science
  • Therapeutics
  • Pharmaceutical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Bluebird Ventures:
Typical Co-investors
Bluebird Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Bluebird Ventures:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Argenthal Aix-en-Provence, France, Provence-Alpes-Côte d'Azur
Atlantic Coast Financial Corporation Georgia, United States, Waycross
Edison Investment Research England, London, United Kingdom
EITACIES California, Santa Clara, United States
FAT Capital Taipei, Taiwan
Grok Ventures Australia, New South Wales, Surry Hills
Hongta Hotland AMC China, Guangdong Province, Huizhou
ICV Partners New York, New York, United States
InterDigital Communications King Of Prussia, Pennsylvania, United States
Japan Post Holdings Chiyoda, Japan
Linear Dimensions Semiconductor California, San Jose, United States
Miami Innovation Fund Florida, Miami, United States
Nautilus Venture Partners California, Palo Alto, United States
Next Floor Austria, Salzburg
ReSolution Underwriting Partnership England, London, United Kingdom
Safe x Connected Cities Accelerator Canada, Ontario, Toronto
Sundaram Mutual Fund Chennai, India, Tamil Nadu
Tier IV -
UIncept Gurgaon, Haryana, India
Wellington West -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Foresight Diagnostics

Biotechnology
Health Care
$33M30 Jul 2024 Denver, Colorado, United States

Foresight Diagnostics

Biotechnology
Health Care
$58M27 Apr 2023 Denver, Colorado, United States

Kriya Therapeutics

Biotechnology
Life Science
$270M16 May 2022 Palo Alto, California, United States

Leyden Labs

Biotechnology
Life Science
Therapeutics
$140M25 Jan 2022 Amsterdam, North Holland, Netherlands

Kriya Therapeutics

Biotechnology
Life Science
$100M14 Jul 2021 Palo Alto, California, United States

Foresight Diagnostics

Biotechnology
Health Care
$12M02 Jun 2021 Denver, Colorado, United States

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$60M23 Sep 2020 California, United States

Kriya Therapeutics

Biotechnology
Life Science
$80M12 May 2020 Palo Alto, California, United States

Epirium

Biopharma
Biotechnology
Health Care
Life Science
$85M19 Dec 2019 San Diego, California, United States
News
Kriya Therapeutics Completes $100 Million Series B Financing to Advance Its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies

– Kriya closed a $100m Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies.
– The financing was led by Patient Square Capital with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others.
– All existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund.
– Proceeds from the financing will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.
– Jim Momtazee, Managing Partner of Patient Square Capital, will join Kriya’s Board of Directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Bluebird Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 11
Average round size 88M
Rounds per year 2.20
Peak activity year 2020
Lead investments 0
Follow on index 0.36
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Foresight Diagnostics

Biotechnology
Health Care
$33M30 Jul 2024 Denver, Colorado, United States

Foresight Diagnostics

Biotechnology
Health Care
$58M27 Apr 2023 Denver, Colorado, United States

Kriya Therapeutics

Biotechnology
Life Science
$270M16 May 2022 Palo Alto, California, United States

Leyden Labs

Biotechnology
Life Science
Therapeutics
$140M25 Jan 2022 Amsterdam, North Holland, Netherlands

Kriya Therapeutics

Biotechnology
Life Science
$100M14 Jul 2021 Palo Alto, California, United States

Foresight Diagnostics

Biotechnology
Health Care
$12M02 Jun 2021 Denver, Colorado, United States

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$60M23 Sep 2020 California, United States

Kriya Therapeutics

Biotechnology
Life Science
$80M12 May 2020 Palo Alto, California, United States

Epirium

Biopharma
Biotechnology
Health Care
Life Science
$85M19 Dec 2019 San Diego, California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: